Safety Profile of Phase I and II Preventive HIV Type 1 Envelope Vaccination: Experience of the NIAID AIDS Vaccine Evaluation Group
- 20 September 1997
- journal article
- clinical trial
- Published by Mary Ann Liebert Inc in AIDS Research and Human Retroviruses
- Vol. 13 (14) , 1163-1177
- https://doi.org/10.1089/aid.1997.13.1163
Abstract
The NIAID-sponsored AIDS Vaccine Evaluation Group was established in 1988 to perform phase I/II clinical trials with candidate preventive HIV-1 vaccines. This report includes safety data from 1398 HIV-negative, healthy volunteers who were enrolled into 25 phase I and 1 phase II multicentered, randomized, double-blind studies evaluating seven recombinant HIV-1 envelope vaccines, two V3 loop synthetic peptide vaccines, and two live poxvirus-vectored recombinant envelope vaccines. All studies but three were placebo controlled; the placebo was either the adjuvant alone or, in studies of recombinant poxvirus vaccines, it was the vector with no gene insert or a non-HIV gene insert. All candidate vaccines were generally well tolerated. The only adverse effects that were clearly related to vaccination were occasional acute local and systemic reactions that were associated with the adjuvants. Three adjuvants in particular were associated with moderate to severe local reactions: alum plus deoxycholate (ImmunoAg), MTP-PE (Biocine Corp.), and QS21 (Genentech, Inc.). MTP-PE was also associated with self-limited severe systemic reactions. There were no serious adverse laboratory toxicities and no evidence of significant immunosuppressive events after receipt of the candidate vaccines. A few volunteers experienced symptoms that might relate to an underlying immunopathologic mechanism (rash, hemolytic anemia, arthralgia), but their presentations were mild and their incidence was low. Eleven volunteers were diagnosed with malignancies during or after their participation, which was within the 95% confidence interval of the number of cases predicted by the National Cancer Institute SEER (Program for cancer surveillance, epidemiology, and end result reporting) database. In conclusion, the envelope-based recombinant or synthetic candidate HIV-1 vaccines appear to be safe and this work has prepared the way for the testing of increasingly complex candidate HIV-1 vaccines.Keywords
This publication has 53 references indexed in Scilit:
- HIV-Specific Cellular and Humoral Immune Responses in Primary HIV InfectionAIDS Research and Human Retroviruses, 1996
- Safety and Immunogenicity of Env 2-3, a Human Immunodeficiency Virus Type 1 Candidate Vaccine, in Combination with a Novel Adjuvant, MTP-PE/MF59AIDS Research and Human Retroviruses, 1996
- Human Studies in the Development of Human Immunodeficiency Virus VaccinesThe Journal of Infectious Diseases, 1995
- Phase I/II Preventive Vaccine Trials: Conference SummaryAIDS Research and Human Retroviruses, 1995
- Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials NetworkJAMA, 1994
- Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1IIIB rgp120 subunit vaccineThe Lancet, 1993
- Transient High Levels of Viremia in Patients with Primary Human Immunodeficiency Virus Type 1 InfectionNew England Journal of Medicine, 1991
- Human retrovirus-related synthetic peptides inhibit T lymphocyte proliferationImmunology Letters, 1988
- Synthetic peptides homologous to HIV transmembrane glycoprotein suppress normal human lymphocyte blastogenic responseCellular Immunology, 1988
- The Prospects for and Pathways toward a Vaccine for AIDSNew England Journal of Medicine, 1985